Lawmakers Reintroduce Bill to Close Loopholes Allowing Big Drug Companies to Block Competition from More Affordable Options The Pharmaceutical Care Management Association, PCMA, applauds Senators Maggie Hassan (D-NH) and Mike Braun (R-IN) for recently reintroducing legislation, the Prescription Drug Competition Act,
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
(Washington, D.C.) — Today, members of the prescription drug supply and payment chain, including pharmacy benefit managers (PBMs), pharmaceutical manufacturers, pharmacies, including specialty and managed care pharmacies, and health plans, sent a letter to Vice President Mike Pence and congressional
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case you missed it, Senator Rand Paul (R-KY) discusses recent legislation advanced by the Senate’s HELP
(Washington, D.C.) — Today, America’s pharmacy benefit managers (PBMs) released a unified industry statement and set of principles on patient access to prescription drugs during the coronavirus outbreak. The principles set forth by PBMs take into consideration the need for
Alex Brill and Angela Banks Dive into the Critical Need for Competition, Big Drug Companies’ Abuse of the Patent System, and Biosimilar Adoption In case you missed it, Angela Banks, Vice President of Policy for the Pharmaceutical Care Management Association
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan sponsors to offer quality, affordable prescription drug benefits. Proposals being pushed to “lower drug costs” that
Most state Medicaid programs have predominantly transitioned the prescription drug benefit to the managed care setting, through which Medicaid managed care organizations (MCOs) and their contracted PBMs collaborate using their prescription drug management and broader care coordination and integration tools.
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
©2024 PCMA. All Rights Reserved.
